600329.SH
达仁堂
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 35.72
+1.05%Year over year
Reported trailing growth
- Revenue
- -25.5%
- EBITDA
- —
- EBIT
- -0.8%
- EPS
- -1.9%
- Free cash flow
- -66.4%
- Operating cash flow
- -61.5%
Forward estimates
Based on analyst estimates
- Revenue
- -46.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -15.8%
- EBITDA
- +33.5%
- EBIT
- +36.4%
- Net income
- +35.2%
- EPS
- +35.2%
- Free cash flow
- -15.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026